π¬ Prior biologic affects anti-TNF durability in IBD patients
The study found that using anti-TNF therapy after different mechanism biologics linked to higher discontinuation risk in ulcerative colitis. This research was conducted using ENEIDA registry data from 2018 to 2025 across 117 UC and 66 CD patients. In UC, discontinuation risk was significantly higher (adjusted hazard ratio, 1.89; P < .001), while CD showed no such association. This suggests the specific mechanism of previous therapy critically influences the subsequent treatment response in IBD. The findings offer real-world evidence on sequential biologic use in IBD management.